Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bugs may guide diabetes therapy, study finds

NCT ID NCT07627048

Knowledge-focused Sponsor: Pirogov Russian National Research Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how gut bacteria affect the development of type 2 diabetes and help personalize treatment. Researchers followed 100 adults newly diagnosed with type 2 diabetes who had not taken diabetes medication before. They analyzed stool samples and blood tests, then assigned different treatments to see how gut bacteria influenced treatment success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Dec 2021

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients were hospitalized at the V.P. Demikhov City Clinical Hospital between October 2019 and February 2021 due to hyperglycemia detected incidentally at their place of residence. The sample consisted of men and women aged 18 to 80 years.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed T2DM * No ketoacidosis * Age ≥ 18 years, ≤ 80 years * BMI \> 25 kg/m2 * No history of taking hypoglycemic drugs (HGD) * No use of drugs that affect BM composition Exclusion Criteria: * Presence of type 1 diabetes * Presence of chronic gastrointestinal diseases: ulcerative colitis, Crohn's disease, celiac disease, irritable bowel syndrome, multiple intestinal polyposis, chronic pancreatitis with frequent exacerbations (more than 6-7 times per year) * Presence of acute gastrointestinal diseases: acute pancreatitis, acute cholecystitis, enteritis, colitis, exacerbation of gastric ulcer or duodenal ulcer * Previous gastrointestinal surgery within the last 3 months Gastrointestinal surgery within the last 3 months. * Severe infectious diseases (HIV, hepatitis B, hepatitis C, tuberculosis, Covid-19) * Glomerular filtration rate (GFR) \< 30 ml/min/1.73 m2 * Mental illness * Alcoholism, drug addiction * Pregnancy or lactation * Cancer * History of blood transfusion, organ transplant, or bone marrow transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes (T2DM)

Contacts and locations

Locations

  • State clinical hospital named after V.P. Demikhov

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.